Improving guidelines for the management of coronary heart disease risk factors by Kappagoda, C. Tissa & Amsterdam, Ezra A.
Improving guidelines for the management of coronary
heart disease risk factors
C. Tissa Kappagoda, Ezra A. Amsterdam
“Best laid plans of mice and men...”
Robert Burns
The accompanying paper by Athyros et al. [1], while drawing attention
to the prognostic importance of renal function in patients with multiple
cardiovascular risk factors, has focused on the larger issue of the practi-
cal difficulties involved in providing this type of care for large numbers of
patients. Their study is a post hoc analysis of 5 observational studies under-
taken in Greece between 2005 and 2010. These studies were designed to
optimize the management of risk factors in patients with various combi-
nations of hyperlipidemia, the metabolic syndrome (as defined by the
American Heart Association and the National Heart, Lung, and Blood Insti-
tute), diabetes mellitus and overt cardiovascular disease. Their intention
was to determine whether a multi-factorial/disciplinary approach would
improve renal function over a 6 month period. The intervention covered
hypertension, dyslipidemia, weight management, smoking cessation, titra-
tion of medications to achieve treatment targets and general lifestyle
changes to promote health.
The primary end-point of the studies was effect of the multi-factorial
intervention on estimated glomerular filtration rate (GFR). The secondary
end-point was the effect of the intervention on serum uric acid. The dis-
tribution of chronic kidney disease (CKD) in the study population (n = 4.153)
was as follows.
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1 912 (22%) > 90 ml/min/1.73 m2
+ renal damage
2 1424 (34%) 60-89 ml/min/1.73 m2
3 1235 (29.7%) 30-59 ml/min/1.73 m2
40 15-29 ml/min/1.73 m2
50< 15 ml/min/1.73 m2
*Number of patients in the table is less than the total number in the study because not all patients
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After 6 months of treatment, there was a 5.6%
improvement in GFR and a reduction of 6.1% in
serum uric acid in stage 3 subjects. Approximately
10% of this category improved to stage 2 while
0.7% advanced to stage 4. In stage 1 and 2 subjects
there was evidence of improvement in the serum
uric acid and body weight but no change in smok-
ing status. The authors concluded that, overall, the
(multi-factorial) intervention was effective.
These benefits have to be viewed against the
background of the magnitude of the intervention
employed in these studies. This included seven
study-related educational meetings for the physi-
cians involved, of which four were devoted to edu-
cation on risk factor management and three to
logistic issues relating to the studies. During the 6
months of the study, the subjects were seen at
monthly intervals (primarily for renewing prescrip-
tions). The physicians used these sessions to rein-
force the aims of the study and the need to make
lifestyle changes such as smoking cessation. The
subjects also met with dietitians who provided addi-
tional information relating to the modified Mediter-
ranean diet that the subjects were prescribed. The
drop-out rate in the various categories of CKD was
said to be similar though no data was provided. The
latter is an important item of information when one
attempts to evaluate the cost-effectiveness of the
intervention, simply because this degree of patient
contact is rarely seen in practice outside the con-
text of a clinical trial. It is clear that intensive
lifestyle interventions have considerable potential
for successful modification of cardiovascular risk
factors, and prior reports have demonstrated these
benefits in impeding development of the metabol-
ic syndrome [2] and in achieving weight loss in
patients with obesity [3]. However, as in the inves-
tigation of Athyros et al. [1], the latter two trials
entailed a very high frequency of patient visits that
included intensive education and counseling pro-
vided by teams of health professionals, Thus, all
three of these studies provide proof of concept but
current systems of medical practice present formi-
dable obstacles that preclude application of these
methods to current clinical care.
Another issue which is likely to have an impact
on whether these findings are generalizable beyond
Greece (or the European Community) is whether
the medications were provided at no cost to sub-
jects. A recent study by Choudhry et al. [4] has
shown that elimination of copayments for drugs (in
the U.S.) after myocardial infarction increased rates
of medication adherence by only 4-6% in those for
whom the drugs were free and the overall rate of
adherence remained at approximately 50%. Fur-
thermore, there was no significant reduction in the
primary outcome of a first major vascular event or
revascularization. 
The flip side of this coin is how physicians
behave when presented with evidence from a clin-
ical trial. Borden et al. [5] examined the impact on
physician practices, of results of the COURAGE tri-
al which compared the efficacy of optimal medical
therapy and percutaneous coronary intervention
(PCI) in patients with stable angina [6]. Despite clear
evidence that optimal medical management was
equally as effective as PCI, there was no percepti-
ble change in the prescribing practices of physicians
toward achieving optimal medical therapy [5]. These
trends are confirmed in another recent study which
sought to examine the efficacy of an Internet-deliv-
ered intervention to physician providers to improve
cardiovascular management of post-MI patients.
The study was undertaken in Veterans Hospitals in
the U.S. over a period of 27 months. It was found
that the Internet-delivered system improved only
1 out of 7 indicators of cardiovascular care in ambu-
latory post-MI patients [7].
Thus, availability of a guideline, evidence from
controlled  clinical  trials  and  free  medications
notwithstanding, there is clearly a need for an alter-
native algorithm for the provision of optimal man-
agement of cardiovascular risk factors.
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